GleamWall
中文EN

BIIB BIOGEN INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 875045 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.3%
TTM net income YoY-78.4%
TTM EPS YoY-78.9%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR-38.1%

Margins

Gross margin74.0%
Operating margin—
Net margin3.4%
FCF margin20.1%
EBITDA margin—

Returns

ROE1.9%
ROA1.1%
ROIC (approx.)—
Asset turnover0.34x

Leverage & solvency

Liabilities / assets41.0%
Debt / equity0.39x
Current ratio1.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income6.47x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue1.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.80B$2.74B$2.48B$2.28B$2.53B$2.65B$2.43B$2.45B
Cost of revenue$748.40M$776.90M$661.00M$495.50M$674.40M$605.00M$629.30M$583.50M
Gross profit$2.06B$1.96B$1.82B$1.78B$1.86B$2.04B$1.80B$1.87B
R&D expense$574.00M$529.60M$539.00M$509.40M$436.10M$399.00M$434.10M$513.30M
SG&A expense$752.00M$709.70M$607.30M$682.50M$594.80M$583.80M$572.50M$680.00M
Interest expense$87.50M$82.30M$67.60M$67.50M$67.40M$72.60M$60.00M$60.00M
Pretax income-$9.00M$132.40M$377.70M-$56.00M$557.30M$744.00M$311.20M$291.50M
Income tax$11.60M$34.90M$58.20M-$7.10M$90.80M$109.20M$70.70M$24.80M
Net income-$20.60M$97.50M$319.50M-$48.90M$466.50M$634.80M$240.50M$266.70M
EPS (basic)-0.140.662.17—3.184.331.65—
EPS (diluted)-0.140.662.15—3.174.331.64—
Weighted avg. shares (diluted)147.80M148.70M148.40M—147.10M146.70M146.60M—
Balance sheet
Cash & equivalents$1.30B$1.28B$3.38B$3.01B$3.86B$2.76B$2.60B$2.38B
Short-term investments$0$0$900.00M$807.20M$97.60M——$0
Receivables———$1.34B———$1.40B
Inventory$2.22B$2.38B$1.95B$2.17B$2.21B$2.27B$2.27B$2.46B
Current assets$7.58B$7.31B$9.19B$8.97B$8.94B$7.97B$7.63B$7.46B
PP&E, net$2.97B$2.99B$3.02B$3.06B$3.08B$3.10B$3.13B$3.18B
Goodwill$6.99B$6.99B$6.49B$6.49B$6.49B$6.49B$6.48B$6.48B
Intangibles$13.38B$13.52B$9.05B$9.18B$9.33B$9.47B$9.58B$9.69B
Total assets$32.05B$32.09B$29.48B$29.44B$29.21B$28.33B$28.03B$28.05B
Current liabilities$3.90B$3.92B$3.00B$3.35B$3.29B$3.18B$5.30B$5.53B
Short-term debt———$0———$1.75B
Long-term debt$7.29B$7.29B$6.29B$6.29B$6.29B$6.28B$4.55B$4.55B
Total debt$7.29B$7.29B$6.29B$6.29B$6.29B$6.28B$4.55B$6.30B
Total liabilities$13.13B$13.24B$10.83B$11.18B$11.00B$10.70B$11.05B$11.33B
Shareholders' equity$18.92B$18.85B$18.65B$18.26B$18.21B$17.63B$16.98B$16.72B
Net debt$5.99B$6.01B$2.91B$3.28B$2.42B$3.52B$1.95B$3.92B
Shares outstanding———146.80M———145.80M
Cash flow statement
Operating cash flow$640.80M$448.90M$645.50M$511.90M$1.27B$160.90M$259.30M$760.90M
Capital expenditure$40.40M$40.90M$51.20M$43.90M$46.20M$26.60M$37.10M$39.30M
Free cash flow$600.40M$408.00M$594.30M$468.00M$1.23B$134.30M$222.20M$721.60M
Investing cash flow-$222.10M-$3.84B-$209.50M-$1.23B-$35.10M-$57.00M-$47.30M-$18.60M
Financing cash flow-$393.80M$1.30B-$43.80M-$137.00M-$130.20M-$11.70M-$23.00M$7.90M
Depreciation & amortization$68.30M$67.90M$204.40M$200.20M$66.50M$66.90M$183.20M$184.00M
Stock-based compensation$81.50M$77.40M$84.00M$59.60M$75.30M$74.90M$81.00M$75.10M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.